PHOENIX MOLECULAR DESIGNS
Phoenix Molecular Designs is developing precise cancer therapeutics with a platform technology focused on developing first-in-class kinase inhibitors designed to uniquely target p90 ribosomal S6 kinase (RSK). Their world-renowned leadership team boasts over 100 years of oncology experience from notable affiliations such as Genentech, Pfizer and Eli Lily. The company completed a Phase 1 first-in-human clinical trial with lead asset, PMD-026, as of Oct 2020, treating women with metastatic breast cancer. A Phase 1b mono-therapy trial is now open in triple negative breast cancer (TNBC) in 9 leading medical centers across the United States.
PHOENIX MOLECULAR DESIGNS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2012-01-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.phoenixmd.ca
Total Employee:
11+
Status:
Active
Contact:
+1 604 674 1796
Email Addresses:
[email protected]
Total Funding:
12.35 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Euro Organization Schema Google Apps For Business
Current Advisors List
Current Employees Featured
Founder
Investors List
The 51 Ventures
The 51 Ventures investment in Seed Round - Phoenix Molecular Designs
Pallasite Ventures
Pallasite Ventures investment in Seed Round - Phoenix Molecular Designs
World Changing Ventures
World Changing Ventures investment in Seed Round - Phoenix Molecular Designs
Pallasite Ventures
Pallasite Ventures investment in Seed Round - Phoenix Molecular Designs
Official Site Inspections
http://www.phoenixmd.ca Semrush global rank: 7.66 M Semrush visits lastest month: 447
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
